Clinical Trial

Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The study is a Phase II, single-arm, open-label, single-dose clinical trial, and its primary objective is to evaluate the efficacy and safety of CNCT19 Cell Injection in the treatment of CD19 positive Relapsed or Refractory acute lymphoblastic leukemia.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2020-12-22; most recent amendment 2025-08-06.
Status change: Not Yet Recruiting → Recruiting 2021-02-09
Trial Details
NCT Number NCT04684147
Lead Sponsor Juventas Cell Therapy Ltd.
Conditions Relapsed or Refractory Acute Lymphoblastic Leukemia
Enrollment 100 participants
Start Date 2020-12-24
Primary Completion 2022-09-22 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-08-08